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Resumen
Introducción: Los inconvenientes de la administración oral pueden controlarse o minimizarse mediante formula-
ciones gastro-retentivas que permanecen flotantes dentro del estómago durante un tiempo prolongado al propor-
cionar una retención gástrica prolongada y liberan el fármaco de una manera excesivamente prolongada mejoran-
do así la biodisponibilidad. La investigación actual fue desarrollar y optimizar las tabletas flotantes de domperidona 
y famotidina con liberación prolongada mediante el enfoque Calidad por diseño.
Método: Basado en QTPP (Perfil de producto objetivo de calidad), se identificaron CQA (Atributos críticos de cali-
dad). El análisis de riesgos mediante la evaluación de los parámetros de formulación y proceso mostró que la op-
timización de los niveles de polímeros podría reducir el alto riesgo para lograr el perfil objetivo. Se seleccionó un 
diseño experimental de 2 factores de nivel 3 con puntos medios para el análisis estadístico y la optimización.
Resultados: HPMC K100, Carbopol 934P tuvo un efecto positivo y la etilcelulosa tuvo un efecto negativo sobre las 
respuestas seleccionadas. La cinética de liberación del fármaco siguió a la liberación de primer orden con difusión 
de Higuchi y difusión de Fickian. Se seleccionó y evaluó una fórmula optimizada que satisfacía todos los parámetros 
requeridos. Los valores de respuesta previstos estaban en estrecha concordancia con los valores de respuesta ex-
perimental. Las imágenes de rayos X abdominales después de la administración oral de las tabletas en el estómago 
sano del conejo confirmaron el comportamiento de flotación prolongado con un tiempo de retraso más corto. Losin 
vivo estudios farmacocinéticosen conejos revelaron que la formulación optimizada exhibía una liberación prolon-
gada del fármaco con una mayor Cmax, tmax, AUCo-t y t1 / 2 del producto
Conclusiones: Se concluyó que la aplicación de Quality by Design en la formulación y optimización redujo el núme-
ro de ensayos para producir una fórmula rentable.
Palabras clave: Carbopol 934P; Tiempo flotante; Etilcelulosa; Calidad por diseño; Imágenes de rayos X.optimizado 
en comparación con el producto comercializado.
Abstract
Introduction: The drawbacks assosiated with oral administration of drugscan be controlled or minimized by gas-
tro retentive formulations that remain buoyant within the stomach for an extended time by providing prolonged 
gastric retention and releasethe drug in an exceedingly extended manner thereby improving bioavailability. The 
current research was to develop and optimize Domperidone and Famotidine floating tablets with extended release 
by Quality by Design approach.
Method: Based on QTPP (Quality Target Product Profile), CQAs (Critical Quality Attributes)wereidentified. Risk anal-
ysis by the evaluation of formulation and process parameters showed that optimizing the levels of polymers could 
reduce high risk to achieve the target profile. A 23factor experimental design with midpoints was selected for statis-
tical analysis and optimization.
Results: HPMC K100 and Carbopol 934P had a positive effect while ethyl cellulose demonstrated a negative effect 
on the selected responses. Drug release kinetics followed the first-order release with Higuchi diffusion and Ficki-
an diffusion. Optimized formula satisfying all the required parameters was selected and evaluated. The predicted 
response values were in close agreement with experimental response values. Abdominal X-ray imaging after oral 
administration of the tablets on a healthy rabbit’s stomach confirmed the extended floating behavior with shorter 
lag time. In vivo, pharmacokinetic studies in rabbits revealed that the optimized formulation exhibited prolonged 
drug release with enhanced Cmax, tmax, AUCo-t, and t1/2 of an optimized product when compared to the marketed 
product.
Conclusions: It has been concluded that the application of Quality by Design in the formulation and optimization 
reduced the number of trials to produce a cost-effective formula.
Keywords: Carbopol 934P; Floating time; Ethyl cellulose; Quality by design; drug release
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Introduction
Gastric retentive dosage forms can monitor gastric emptying time and prolong the release of dosage 
forms in the stomach region for a longer period than the traditional dosage forms. The extended re-
lease dosage delivery forms were designed for improved drug absorption and enhanced bioavailability 
that opposes several difficulties(1). Floating drug delivery systems (FDDS) are low density systems that 
have enough resilience to float over the gastric contents and persist in the stomach for an extended 
period. Buoyancy can improve retention time and reduce dosing frequency. An effervescent system 
produces gas (CO2) which increases the system density and remains buoyant inside the stomach
(2).
Domperidone and Famotidine are highly specific drug(s) which are used in the treatment of vomiting 
and hyperacidity. Domperidone acts on upper GIT to upsurge the stomach and intestine movements, 
allowing food to move and that controls the vomiting. Famotidine is a H2 blocker that diminishes the 
acid level in the stomach to get relief from indigestion and heart burn. The approximate absolute bio-
availability of Domperidone is 13- 17% and Famotidine is 40-45%. This can be improved and maxi-
mized by improving bioavailability and by increasing retention of these drug(s) in upper GIT. Marketed 
dosage form needs repeated administration atleast 3 times a day to achieve therapeutic activity there 
by imposing unwanted side effects and this problem can also be avoided by FDDS(3,4).
The focal objective of the current study was to prepare an effervescent floating drug delivery system 
with extended release, which increases the bioavailability, patient compliance, and will diminish the 
administration frequency. In this study, Domperidone and Famotidine combination (DFC), tablets 
with effervescent floating were developed and optimized by Quality by Design (QbD) implementation. 
QbD is a tool in which the development of formulations will be carried out by risk assessment, con-
struction of design space withinbuilt quality, and exhibits flexibility as per regulatory guidelines(5). The 
experiments were deliberated by the implementation of Design Expert 11 software. In preliminaries, 
the Quality Target Product Profile (QTPP) was defined, and Critical Quality Attributes (CQA’s) were in-
vestigated. Risk assessments were made to select the critical variable in formulation development. A 
Full Factorial design was selected to design the experiment (DoE) and thereby assessing continuous 
improvement for maintaining quality(6).
Méthodes
Materials
Domperidone was acquired from Vector biosciences PVT Ltd, Hyderabad and Famotidine from Divis 
laboratory as gift samples. Excipients used were HPMC K100, Carbopol 934P, Ethylcellulose, Sodium 
bicarbonate, Magnesium stearate, Talc, and Lactose purchased from SD fine chemicals, Mumbai.
Methods
Quality by Design (QbD) implementation
Quality Target Product Profile (QTPP) of the proposed drug delivery system
QTPP is a needed document that enables the formalization and tracing of the evolution of the knowl-
edge acquired throughout the drug lifespan. Based upon the Reference Listed Drug (RLD), require-
ments and targets were set up for QTPP(7).
Critical Quality Attributes (CQA’s) of proposed drug delivery system
Relevant CQAs can be known by a frequent process of quality risk management and experimentation 
which assesses the quality of the drug product.
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Risk Assessment by using QTPPs and CQAs
A risk assessment of the drug substances attributes was made to assess the impact of each attribute on 
the drug product CQAs.
Design of Experiment (DoE)
DoE is a prevailing skillful experiment, conducted in randomized order. The number of experiments 
required depends upon the selected design which curtails the number of trials. Optimization was exe-
cuted by two-level, three-factor (23) full factorial design using Design Expert 11 software. Independent 
variables (HPMC K100M, Carbopol 934P, and Ethylcellulose (EC)) and dependent variables (Floating 
time, percentage cumulative drug release at 2 h, 12 h, and t50%) were selected for optimization based 
on risk assessment of data(8).
Drug-excipient interaction compatibility studies
An FT-IR spectrum was recorded by the KBr pelletization method (FT-IR Bruker model). 2 mg of the 
pure drug(s) (Domperidone, Famotidine) were dispersed in Potassium bromide powder (KBr) and by 
pressurizing 6 tons the pellets were prepared and scanned separately. Individually the spectra were 
compared for validation of common peaks. The same procedure was adopted for FTIR study of drug(s) 
with excipients
5 mg drugs (pure) and drug(s) with excipients were placed into DSC aluminum pan (DSC-60, Shimadzu) 
separately and then scanned at the temperature range of 25-2900C of heating increment of 15 0C/min, 
then the obtained thermographs of the drug(s) (pure) and with excipients was equaled for interaction(9).
Preparation of Domperidone and Famotidine Effervescent Floating tablets
All the ingredients were collected and weighed precisely. In addition to the previously formulated APIs 
and Carbopol mixture, the geometric mixture of HPMC K100, Ethyl cellulose (EC), sodium bicarbonate, 
and filler was added and mixed well along with Talc (2%) and magnesium stearate (1%) then passed 
through the 60# sieve. The lubricated mixture was compressed using round tooling on Rimex-I rotary 
tablet machine.
Design Space
In terms of ranges of material attributes and process parameters, Design space was defined. The linear 
formula is as given below(10).
Y = b0+ b1X1.+ b2X2+b3X3+b4X4+…………..bnXn
Where Y is considered as a response, b0 is the constant, b1 b2 …….bn is the variables X1 X2........Xn is repre-
senting the effect every ordered between -1 and +1.
Control strategy
The parameters and attributes were included in control strategy such as drug type, pharmaceutical 
materials, and components, operating conditions of facilities and equipment, in-process controls, 
specifications of finished products, allied methods(11).
Physical characterization of floating tablets
The tablets were screened for organoleptic characters, hardness (using monsanto hardness tester), 
thickness (using digital vernier calipers), % friability (25 rpm in roche friabilator), weight variation. Con-
tent uniformity was determined by randomly collecting twenty tablets and by crumbling in mortar and 
pestle. Then the requisite quantity of the drug(s) were transferred into a 100 ml volumetric flask. To 
this, 0.1 N HCl was added, followed by mechanical shaking for 5 min and filtration. Several dilutions 
were made and finally, 10ml/µg was evaluated to determine the drug content at 284 nm (Domperi-
done), 260 nm (Famotidine) by UV-Visible spectrophotometer simultaneous estimation method(12,13).
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In vitro Floating studies
The test was performed using USP Type-II apparatus paddle using 900 ml of 0.1N Hydrochloric acid 
(HCl) as a dissolution medium at 75 rpm at 37°C ± 0.5°C . The time taken for a tablet to float on the 
medium surface was noted which was considered as floating lag time. The time duration of the tablet 
to float constantly on the medium was considered as floating time.
In vitro Dissolution studies
USP Type-II (Paddle) apparatus, 0.1 N Hydrochloric acid (HCl) as a dissolution medium at 75 rpm at 
37°C ± 0.5°C were the maintained parameters. At the regular time intervals (1, 2, 3, 4, 5, 6, 8, 12) h, the 
samples were withdrawn by using a syringe fixed with a pre-filter and replaced with fresh 0.1 N Hydro-
chloric acid (HCl) media. Cumulative percentage drug release was analyzed at 284 nm (Domperidone) 
and 260nm (Famotidine) by the developed HPLC technique(14).
Statistical data optimization and analysis
The obtained formulations data were scrutinized by Design expert 11 software to generate study de-
sign.
Half normal plots, Pareto chart, and ANOVA data were used to identify and to select a significant factor 
that affects the formulation development. Design space was created by model graphs, their interac-
tions, contour plots, 3D surface response plots, and overlay plots.
Analytical development for dissolution samples (HPLC)
Standard and blank solution preparation
The standard solution was prepared by dissolving the drug(s) Domperidone (20mg) and Famotidine 
(20mg) in a buffer (15ml) and acetonitrile (10ml) and transferred into a 25 ml volumetric flask and son-
icated for 5min, then filtered through 0.45µm membrane filter. The concentration of the solution was 
found to be 1.6mg/ml. The blank solution which was used as the mobile phase was prepared as similar 
to standard without the pure drug(s) in the ratio of 60:40% v/v mixtures of Phosphate buffer and ace-
tonitrile(15).
Sample preparation
The collected dissolution samples equal to 10mg of Domperidone and 20mg of Famotidine were trans-
ferred to a 25 ml volumetric flask. The sample was dissolved and diluted with the mobile phase and 
subjected to sonication for 10min, filtered through a 0.45µm membrane filter.
Chromatographic Conditions: The HPLC separation and quantification were carried out using a sta-
tionary phase composed of Analytical column-Phenomonex-Gemini, C- 18 (250x4.6mm id,5μ). The mo-
bile phase composed of potassium dihydrogen phosphate buffer-acetonitrile-methanol (40:40:20) was 
pumped at a flow rate of 1ml per min, and the run time was 7 minutes. The mobile phase was filtered 
through a 0.45μm membrane filter and degassed using an ultrasonic bath. The system was equilibrated 
and saturated with the mobile phase for half an hour before the injection of the solutions. All determi-
nations were carried out at room temperature. The absorbance was measured at 284nm and 260nm. 
20µL was the Injection volume. The peak areas were taken to quantitatively determine the amount of 
drug(s) present in the sample. Further based on the amount of drug(s) %, cumulative % drug release 
was calculated(16).
Stability studies
Tablets of the optimized formulation were filled in HDPE containers to carry out stability studies at 40° 
C ±2°C /75% ± 5% RH for 3 months. The optimized formulation was evaluated for hardness, floating lag 
time, drug content and in vitro drug release studies after 3 months.
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In vivo Study protocol
Ethical clearance
The study was performed after obtaining approval from the Institutional Animal Ethics Committee 
(IAEC). A total of 6 rabbits were considered and from that 2 were used for in vivo floating behavior and 
4 were used for pharmacokinetic studies.
In vivo floating behavior
In vivo floating behavior of optimized floating formulations was studied in healthy rabbits, weigh-
ing 1.5 – 2.5 kg. The study was conducted with the prior approval of the Institutional Animal Ethical 
Committee. The study is constructed on the principle of monitoring radiological activity. Animals are 
housed individually in polypropylene cages and maintained under standard conditions. A total of 2 
rabbitsTotal 2 rabbits were involved in the study. The rabbits were fasted for 12h before initiating the 
study. First, an X-ray was taken from the rabbits to ensure the absence of radio-opaque material in the 
stomach. During the study, animals were not allowed for food but the water was provided ad libitum. 
Radiopaque formulations were prepared by incorporating 500 mg of barium sulfate into the optimized 
formulation. At varying time intervals, X-ray photographs of the gastric region were taken for monitor-
ing the floating behavior of formulations(17).
Experimental design
Four healthy rabbits with a bodyweight range of 1.5-2.5 kg were selected through physical examina-
tion. An open label, balanced, randomized, Two-period, Two-treatment, Two -sequence, single-dose 
crossover study design in which four healthy rabbits received one treatment (product) each with a 
washout period of 7 days such that all products are tested in all the four healthy rabbits during the 
study(18). Each healthy rabbit receive the following treatment in random order given in (Table 1)
Table 1: Two- way crossover treatment study for the selected optimized formulations
Animal Sequence 1 Washout Sequence 2
Animal 1 Optimized tablet Marketed formulation
Animal 2 Marketed formulation Optimized tablets
Sequence 1 Washout Sequence 2
Animal 3 Optimized tablet Marketed formulation
Animal 4 Marketed formulation Optimized tablets
Drug administration
The animals were fasted overnight before administering the dose. After collecting the zero hour blood 
sample (blank), a standardized diet was given. The healthy rabbits were fixed in an individual rabbit 
holder with its head protruding outside. Then a mouth gag was introduced in between the two jaws 
and held in position by holding the upper jaw and lower jaw with a left hand and fixed formulations 
were administered through the oral route with the help of a pet piller. An I.V. cannula, 20-G KitKath (Hin-
dustan Syringes &Medical Devices, Faridabad, India) was inserted into one marginal ear vein for blood 
collection before drug administration(19).
Blood sample collection
During each period, 0.5 ml venous blood samples were collected from the marginal ear veins of each 
rabbit in AcCuvet tubes (Quantum Biologicals Pvt. Ltd., Chennai, India) containing K3EDTA. Blood Sam-
ples were collected at predetermined time intervals of 0, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 
8.00, 12.00 and 24.00 h (11 intervals). The collected plasma was immediately separated by centrifu-
gation at 7500 rpm for 15 min from the blood samples and stored in frozen conditions at -20°C before 
analysis. The concentration of each drug in rabbit plasma samples was measured by the HPLC method.
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Determination of pharmacokinetic parameters
Pharmacokinetic parameters such as peak plasma concentration (Cmax), time at which Cmax occurred 
(Tmax), area under the curve (AUC), elimination rate constant (Kel), biological half-life (t½), absorption 
rate constant (Ka) and mean residence time (MRT) were calculated in each case using the data by Kinet-
icaTM 2000 software (Inna Phase Corporation, U.S.A) using non-compartmental approach(20).
HPLC Method
The components were separated using Phenomenex-C18 (4.6 mm id, 250 mm, 5μm) column using 
Methanol: 0.1% orthophosphoric acid in water (55:45% v/v) as mobile phase at a flow rate of 1.0 ml/
min. The eluents were detected at 284nm (Domperidone), 260nm (Famotidine) using a UV detector.
Rehabilitation
Animals were kept for a washout period of 1 week and rehabilitees. No anesthesia was given and eutha-
nasia was not applicable, as there was no sacrificing of animals to relieve pain and suffering.
Results
QbD (Quality by Design) implementation and optimization
QTPP was carried out on Domperidone and Famotidine combination drug for the preparation of the 
desired formulation, needed in the final product. It was demonstrated in (Table 2).
Table 2: Quality Target Product Profile (QTPP) of Proposed Drug Delivery System
QTPP Target Requirement
Dosage Form Extended release Floating Tablets To reduce the gastric emptying and 
to enhance the oral bioavailability
Route of administration Oral Same route of administration
Dosage strength 10mg & 20mg Pharmaceutical equivalence re-
quirement: same strength
Weight of the dosage form Not more than 400mg Patient Compliance
Stability study The Product should be stable for 24 
months
To establish the shelf life of drug 
products.
Hardness in case of floating tablets Not less than 4kP Hardness impacts dissolution.
Floating lag time Should be within 15 minutes Required as a part of the ideal char-
acteristics of FDDS
Floating time Should be floated in an acidic 
environment for at least 12 hours or 
more than 12 hours
Ideal for FDDS
Dissolution USP Apparatus –II (Paddle)
Media: 0.1 N HCl
RPM: 75
Volume 900 mL
Time Points: 0.25, 0.5, 1, 2, 4, 6, 8, 10 
and 12 h
Extended release with First-order for 
a minimum of 12 hours is expected 
for an FDDS to improve the bioavail-
ability
Assay 95.0% to 105.0% for both the drugs Needed for clinical effectiveness.
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QTPP Target Requirement
Pharmacokinetics Cmax: Within 2 hours
Maximum Residence Time should 
be higher than marketed drug
Bioavailability: Should be higher 
than marketed drug
Objective is to increase the bioavail-
ability of both the drugs
CQAs were identified based on the safety and efficacy of the formulation and elaborated in (Table 3).
Table 3: Critical Quality Attributes (CQAs) of a Proposed Drug product
Drug product Target Is a CQAs Level of risk Justification
Hardness in case of 
floating tablets
Not less than 4kP No NA Hardness impacts dissolution. 
However, it will be extended 
during compression.
Identification Test HPLC: Retention time 
of the principal peak 
in the chromatogram 
should be equal to the 
same as that of the 
standard solution in the 
estimation of related 
substances.
Yes Low Though identification was critical 
for safety and efficacy, this CQA 
can be effectively extended by 
the quality management system 
and will be monitored at drug 
product release. Formulation and 
process variables do not impact 
identity. Therefore, this CQA will 
not be discussed during formula-
tion and process development
Floating lag time Should be floated with-
in 15 minutes
Yes Medium Required as a part of ideal 
characteristics of floating drug 
delivery system
Floating time Should be floated in an 
acidic environment for 
at least 12 hours
Yes High Ideal for floating drug delivery 
system
Dissolution USP Apparatus –II 
(Paddle)
Media: 0.1 N HCl
RPM: 75
Volume 900mL
Time Points: 0.25, 0.5, 
1, 2, 4, 6, 8, 10 and 12 
Hours
Yes High Failure to meet the dissolu-
tion specification can impact 
bioavailability. Both formulation 
and process variables affect the 
dissolution profile. This CQA 
will be investigated throughout 
the formulation and process 
development
Assay 95.0% to 105.0% for 
both the drugs
Yes High Assay variability will affect safety 
and efficacy. Process variables 
may affect the assay of the drug 
product. Thus, the assay will be 
evaluated throughout product 
and process development.
After preliminary trials and from the risk assessment, initially, HPMC K 100M, Carbopol 934P, Ethylcel-
lulose (EC) were selected as independent variables to study their effect on dependent variables. Hence 
23 Full factorial design was selected for the present study, it was set at two levels three factors with four 
midpoints. From the four midpoints the average was considered. (Formulations were 8, and average 
mid-point was 1, and a total of 9 formulations were performed). Risk assessment was demonstrated in 
(Table 4) and (Table 5).
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Table 4: Risk assessment for formulation variables
Drug product CQA HPMCK100 Carbopol 934P Ethyl Cellulose
Assay Low Low Low
Hardness High High High
Floating time High High High
Dissolution High High High
Table 5: Justification for risk assessment for formulation development





Extended-release of the drug from 
tablet depends upon proper hard-
ness which directly affects the drug 
release. Efficient floating effective 





The presence of talc at a low level 
may not affect assay, drug release. 
Hence the risk was low.




A Low amount of the lubricant 
diminishes the effect and hence 
low risk.
Design of Experiment (DoE)
In Design of Experiment (DoE), Y1 was floating time, Y2 was drug release at 2 h, Y3 was drug release at 12 
h, and Y4 was time taken to release 50% drug were considered as dependent variables and Independent 
variables were X1 (HPMC K 100), X2 (Carbopol 934P), X3 ( Ethyl Cellulose)
Drug-excipient interaction compatibility studies
FTIR of the pure drug and pure drug with excipients showed that there was no incompatibility with 
excipients used and were found to be compatible.
DSC thermographs showed the melting point of pure drug Domperidone at 251.90C and with excipients 
at 260.80C. The melting point of the pure drug Famotidine was observed at 168.690C and with excipi-
ents at 179.590C. By this, it was proved that there were no major shifts and indicated that no, physical 
and chemical interactions.
Physical characterization of floating tablets
Organoleptic characteristics showed that both the drugs (Domperidone and Famotidine) were white 
color and odorless. Formulations (F1-F9) were prepared and pre-compression parameters indicated 
that the prepared blend had good free-flowing property. Compressibility index (CI), Hausner’s ratio, 
and angle of repose were found to be in the range showed in (Table 6). Tablets were evaluated for Post 
compression parameters which were complied with acceptable variation as per IP specifications. The 
tablet thickness was found to be 4.12 to 4.15 mm and hardness was found to be 5.39 to 5.89 kg/cm2, 
the friability values of all the formulations were less than 1% as per IP limits. The percentage of drug in 
the developed tablets was found to be 93.5 to 100.3 of Domperidone and 95.4 to 100.3 of Famotidine.
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Bulk density (g/cc) 0.49 0.52
Tapped density (g/cc) 0.65 0.68
Carr’s Index 32.65 30.77
Hausners Ratio 1.33 1.31
Angle of Repose 28.3 27.4
In vitro floating studies
All the selected optimized formulation tablets were placed in 0.1N HCl dissolution medium separately 
(n=9) and the floating lag time of all tablets was found to be 5 to 12 mins. Due to the presence of gas 
generating agent (Sodium bicarbonate) the effervescence was observed.
In vitro Dissolution studies
The formulations with a high concentration of carbopol 934P and low concentration of ethyl cellulose 
and HPMC K 100 exhibited extended release criteria i.e., NMT 20% release in 2 h and NLT 80% in 12 h. 
All formulations followed the first-order kinetics with Higuchi diffusion (r2=0.999) and fickian diffusion 
(n≤0.5). In vitro drug release of Domperidone and Famotidine is delineated in Figure 1
Figure 1: (a) In vitro drug release of Domperidone (b) In vitro drug release of Famotidine
All values were expressed as Mean±SD, n=6
Discussion
Multiple regression analysis
Response (R1) analysis: Floating time (Y1)
Responses ranged from 5 min to 18 min and the ratio of maximum to a minimum is 3.6 that indicated 
no need for power transformation. The final equations of the reduced model contain only significant 
factor terms corresponding to the response analyzed.
Floating time (Y1) = 12.20 + 1.00 X1 + 1.01 X2 + 5.24X3 +0.81 X1X2 +0.66 X2X3
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From the ANOVA results, it was found that the main factors affecting the floating time were X1, X2, X3, 
X1 X2, X2 X3. All factors had a synergistic effect. The adjusted F- value is 4.81 and the model p-value is 
0.0119. The curvature term was removed to simplify the analysis. In the Fit Statistics section, the Pre-
dicted R² of 0.9789 is in reasonable agreement with the Adjusted R² of 0.9900. The Adequate precision 
ratio is 6.882 which was considered an adequate signal. Contour plots and 3D plot showed that, to max-
imize floating time (more than or up to 12 h) the concentrations of HPMC K100 (X1) and Carbopol 934P 
(X2) should be maintained at high levels i.e., 43.8mg (X1), 45.0mg (X2). At this concentrations, the floating 
time was 12.1 h. The perturbation plot showed that as As the concentration of HPMC K100, Carbopol 
934P, and ethyl cellulose increased, the Floating time also increased. The Contour plot and the 3D plot 
is indicated in (Figure 2(a)) and (Figure 3(a))
Response (R2) Analysis: Drug release at 2 h (Y2)
Responses range from 10.5% to 39.7% and the ratio of maximum to a minimum is 3.78 that indicated 
no need for power transformation.
Drug release at 2 h (Y2) = 24.08 – 2.54 X1 + 1.37X2 – 6.34 X3 + 3.18X1X3 – 1.76 X2X3
From the ANOVA results, it was found that the major factors affecting drug release at 2 hwere X1, X2, X3, 
X1X3, X2 X3. Factors X1 and X3 exhibited a antagonistic effect while all other factors had a synergistic ef-
fect, The adjusted F- value was 5.01 and the model p-value was 0.0089. The lack of fit F-value of 275.96 
implied that it was significant. In Fit Statistics section, the Predicted R² of 0.5272 is in reasonable agree-
ment with the adjusted R² (0.3276). Adequate precision ratio was 7.436 indicating an adequate signal. 
Contour plots and 3D plot showed that in order to maintain drug release NMT 20%, HPMC K100M and 
ethylcellulose should be maintained at low levels and carbopol 934P should be maintained at high 
levels. By maintaining the concentrations of HPMC K100M, Carbopol 934P and Ethylcellulose at 45mg 
(X1), 45mg (X2) and 15mg (X3) then the drug release was NMT 20%. The perturbation plot showed that an 
increase in the concentration of HPMC K100M and ethylcellulose led to decrease in drug release and an 
increase in the concentration of carbopol 934P resulted to increase in drug released. Contour plot and 
3D plot is indicated in (Figure 2(b)) and (Figure 3(b))
Response (R3) Analysis: Drug release at 12h (Y3)
Responses ranged from 86.4% to 101.3% and the ratio of maximum to a minimum is 1.17 that indicated 
no need for power transformation.
Drug release at 12 h (Y3) = 97.53 + 1.14 X1 + 1.63 X2 -1.94 X3 – 1.04 X1X2 + 1.98 X1X3+ 0.8813 X2 X3
From the ANOVA results, it was found that the major factors affecting the Drug release at 12 h were X1, 
X2, X3, X1X2, X1 X3, X2 X3. Factor X3 exhibited an antagonistic effect while the remaining factors had a syner-
gistic effect. The Adjusted F- value was 4.33 and the model p-value was 0.0218. The Lack of Fit F-value 
of 3.43 implies that it was significant. In the Fit Statistics, the Predicted R² of 0.9361 is in reasonable 
covenant with the Adjusted R² of 0.9610. The Adequate Precision ratio was 4.548 indicatingan ade-
quate signal. Contour plots, 3D plot have shown that to maintain drug release NLT 80% Ethylcellulose 
should be maintained at low levels and HPMC K100M and Carbopol 934P should be maintained at high 
levels. By maintaining the concentrations of HPMC K100M, Carbopol 934P, and Ethylcellulose at 45mg 
(X1), 45.0mg (X2), 15mg (X3) then the drug release is NLT 80%. The perturbation plot shows that as an 
increase in the concentration of ethylcellulose the drug release is decreased and an increase in the 
concentration of HPMC K100M and Carbopol 934P the drug release also increased. The Contour plot 
and 3D plot are indicated in (Figure 2(c)) and (Figure 3(c)).
Response (R4) Analysis: Time taken to release 50 % drug (Y4)
Responses range from 3.8 h to 7 h and the ratio of maximum to a minimum is 1.84 that indicates no 
need for power transformation.
Drug release at 12 h (Y4) = 5.34 + 0.3750 X1 – 0.4750 X2 + 0.2125 X3 + 0.0375 X1X2 + 0.1500 X1X3+ 0.5500 X2X3
From the ANOVA results, it was found that the major factors affecting the floating time were X1, X2, X3, 
X1X2, X1 X3, and X2 X3. Factor X2 had an antagonistic effect while the other factors had a synergistic effect. 
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The adjusted F- value is 14.57 and the model p-value was less than 0.0001. The Lack of Fit F-value 10.55 
implicates that Lack of Fit is significant. In Fit Statistics, the Predicted R² of 0.6318 is an injudicious 
agreement with the Adjusted R² of 0.8190 i.e. the difference is less than 0.2. This indicated there was 
no large block effect on the model so no need for model reduction and response transformation. The 
Adequate Precision ratio was 11.350 indicated an adequate signal. Contour plots, 3D plot showed that 
to maintain extended drug release (50%) HPMC K100M and Ethylcellulose should be maintained at 
high levels and Carbopol 934P should be maintained at low levels. By maintaining the concentrations 
of HPMC K100M, Carbopol 934P and Ethylcellulose at 43mg (X1), 44.8mg (X2), 15mg (X3) then the drug 
release (50%) was achieved at 5.6 h. As perturbation plot showed that as an increase in the concentra-
tion of HPMC K100M and Ethylcellulose the drug release increased and an increase in the concentration 
of Carbopol 934P the drug release also decreased. Contour plot and the 3D plot is indicated in (Figure 
2(d)) and (Figure 3(d))
Figure 2: Contour plots of a) Response (R1), b) Response (R2), c) Response (R3), d) Response (R4)
From all the responses, the ANOVAresults exhibited significance hence were selected for further analy-
sis. The model was used to navigate the design space. All factor graphs and interaction graphs showed 
LSD bars around the predicted mean, which were good quick pair wise comparisons. From the Half-nor-
mal plot and Pareto Chart, significant factors were identified i.e., above t-value. The normal probability 
plot residuals followed a normal distribution i.e., followed a straight line as shown in (Figure 4).
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Figure 3: 3D surface response plots of (a) Response (R1), (b) Response (R2), (c) Response (R3), (d) Response (R4) all 
four responses.
Figure 4: Plots exhibiting significance at p <0.05 (a) Half normal plot (b) Pareto chart
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It was evident from the plots of Residuals versus Predicted, Residuals Versus Run that error terms were 
not associated with one another and it adequately showed that the model fits the data obtained from 
Software. Predicted Versus Actual plot data points exhibited a split by the 45-degree line indicated sig-
nificance. Cook’s distance provides valuable information regarding the measurement of regression ef-
fect changes if the case is deleted, large values should be identified which were produced by recording 
errors and should be corrected. In this case, no large values were observed it indicated the data without 
any errors. All were shown in (Figure 5).
Figure 5: Plots exhibiting significance at p <0.05 (a) Normal plot (b) Residual versus Run (c) Box-Cox plot (d) Cook’s 
distance
To optimize all responses with different targets, a multi-criteria decision approach like a numerical 
optimization technique by desirability function and graphical optimization technique by the overlay 
plot were used and represented in (Figure 6). The optimized results gave a solution with theoretical 
target profile characteristics which were shown in (Table 7) relative errors (%) between the predicted 
and experimental values for each response were calculated and values were found to be within 1.018. 
the experimental values were in agreement with the predicted value confirming the predictability and 
validity of the model.
Table 7: Comparison of experimental results with predicted responses of Domperidone and Famotidine
Ingredient Composition 
(mg/tab)
Response Predicted value Experimental 
value
Standard error
HPMC K100 45 Y1 h 12.24 11.51 0.365
Carbopol 934P 45 Y2 % 23.47 24.89 0.71
EC 15 Y3 % 97.6 98.1 0.25
Y4 h 5.3 5.9 0.3
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Figure 6: Overlay plot- graphical optimization technique.
In vivo studies
In vivo Buoyancy Studies
The X-ray images were taken after administration of barium sulfate loaded optimized floating tablets to 
the rabbits under fasting conditions. (Figure 7) shows X-ray images at different time intervals i.e, 0h, 6h, 
and 12h in the rabbit. It was observed that the tablet remained in the gastric region for more than 12h.
Figure 7: X-ray images of buoyant behavior in rabbit (a) at 0h (b) at 6h(c) at 12h
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Pharmacokinetic assessment
The mean plasma concentration of the Domperidone and Famotidine both test and reference in (Ta-
ble 8). (Figure 8) shows the comparative plasma profiles of Famcool-D Marketed formulation (R) with 
Domperidone and Famotidine. The mean peak plasma concentration (Cmax) of the test (T) formulation 
was less when compared with the reference (R) formulation. The increase in tmax clearly indicated the 
drug availability for a prolonged period. After reaching the tmax the drug started elimination and plasma 
concentration gradually decreased. In the case of the test (T) formulation, the tmax achieved slowly and 
the drug availability was found for a long time. The increase in AUC0-t was observed in the test (T) for-
mulation, which was clearly indicated the drug availability for a long duration. The plasma elimination 
half-life (t1/2) of the reference (R) and the test (T) formulations were significantly different. Thus the pro-
longed t1/2 is another indication of the in vivo performance of the optimized floating tablets. The overall 
Cmax, tmax, AUCo-t, and t1/2 were completely different between both the test and reference formulation. 
Therefore the developed formulations released the drug for a prolonged period of time.
Table 8: Pharmacokinetic parameters of optimized tablets of Optimized formulation and Marketed product
Parameter Unit Optimized Formulation Marketed Formulation
Domperidone Famotidine Domperidone Famotidine
Lambdaz 1/h 0.05 0.05 0.06 0.07
t1/2 H 14.56 14.35 12.19 10.29
tmax H 2.50 2.50 2.00 2.00
Cmax ng/ml 43.40 85.16 45.60 89.46
Clast_obs/Cmax 0.09 0.09 0.13 0.08
AUC 0-t ng/ml*h 390.69 748.88 262.21 448.91
AUC 0-inf_obs ng/ml*h 433.21 824.82 365.11 551.69
AUC 0-t/0-inf_obs 0.90 0.91 0.72 0.81
AUMC 0-inf_obs ng/ml*h^2 4479.61 8282.15 6361.59 7057.20
MRT 0-inf_obs H 23.45 23.57 17.42 12.79
Vz/F_obs (mg/kg)/(ng/ml) 0.01 0.01 0.02 0.02
Cl/F_obs (mg/kg)/(ng/ml)/h 0.00104 0.00 0.00123 0.00
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Figure 8: Plasma concentration time profile of (a) Domperidone and (b) Famotidine
All values were expressed as Mean±SD, n=4
Stability studies
The optimized formulation showed no significant changes in the hardness and in vitro drug release 
studies after 3 months and indicated the stability of the developed formulations.
Conclusion
floating tablets of Domperidone and Famotidine exhibited extended release for more than 12 h. The 
formulated and optimized tablets showed improvement in bioavailability where dosage frequency can 
be reduced with improved patient compliance. By the Risk assessment technique, the factors and re-
sponses that affect the quality of the product were assessed. 23 factorial design with midpoints could 
be successfully applied for the development of floating tablets with fewer trials and better quality at-
tributes. The In vivo evaluation of the prepared floating tablets proved the improved bioavailability of 
drugs with increased plasma concentration more than 12 hours equal to that of commercial tablets 
that extended for 10 h. Hence, the amount of the drug and the number of administration per day were 
reduced. The further study can be extended to humans (clinical trials) to prove its side effects that 
could be predicted with this developed floating drug delivery system.
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